Galderma’s shares slumped the most in more than a year after US regulators turned down the Swiss dermatology firm’s rival Botox treatment Relfydess.
Usefull Links
Articles
Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
© 2026 smsanews.com. All rights reserved. Designed by DD.

